Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

NCT05269134 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-11-30

No results posted yet for this study

Summary

This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.

Conditions

  • Prosthetic Joint Infection

Interventions

DRUG

Bacteriophage

Phage Therapy

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Adaptive Phage Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edward Fang, MD · Adaptive Phage Therapeutics, Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-27
Primary Completion
2025-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269134 on ClinicalTrials.gov